Sensitivity of Self-collected Skin Sampling for Scabies: a Pilot Study
SCRAPE
1 other identifier
interventional
144
1 country
1
Brief Summary
In this cross-sectional diagnostic study, healthy adults aged 18 and older with suspected, clinical, or confirmed scabies will be recruited. The objective is to determine if the sensitivity of self-collected skin samples for scabies diagnosis is non-inferior to professional sampling, and compare the sensitivity and specificity of the polymerase chain reaction assay (PCR) versus microscopy.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for early_phase_1
Started Aug 2024
Shorter than P25 for early_phase_1
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 26, 2024
CompletedFirst Posted
Study publicly available on registry
August 9, 2024
CompletedStudy Start
First participant enrolled
August 21, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2025
CompletedAugust 9, 2024
July 1, 2024
9 months
July 26, 2024
August 6, 2024
Conditions
Outcome Measures
Primary Outcomes (2)
The sensitivity of self-collected skin samples for diagnosing scabies
The proportion of self-collected samples collected at the enrolment visit that are tested positive, divided by the total number of participants adjudged retrospectively to have had scabies at their enrolment visit, based on a composite clinical diagnosis.
through study completion, an average of one year
The sensitivity of professionally-collected skin samples for diagnosing scabies
The proportion of professionally-collected samples collected at the enrolment visit that are tested positive, divided by the total number of participants adjudged retrospectively to have had scabies at their enrolment visit, based on a composite clinical diagnosis.
through study completion, an average of one year
Secondary Outcomes (4)
The sensitivity of skin scrapings for diagnosing scabies
through study completion, an average of one year
The sensitivity of skin swabs for diagnosing scabies
through study completion, an average of one year
The sensitivity and specificity of PCR on skin scraping for diagnosing active scabies infection
through study completion
The sensitivity and specificity of microscopy on skin scraping for diagnosing active scabies infection
through study completion, an average of one year
Other Outcomes (3)
Proportion of participants whose self-sampling location is judged appropriate
through study completion, an average of one year
Motivation for self-collection of skin samples for scabies diagnostics
through study completion, an average of one year
Demographic, clinical and epidemiological factors which influence the sensitivity of self-collected skin samples for scabies diagnosis.
through study completion, an average of one year
Study Arms (1)
Experimental group
EXPERIMENTALAll participants will be asked to perform self-sampling and irrespective of the result will receive current standard-of-care from their health care provider for their suspected scabies.
Interventions
All individuals will self-collect skin samples and swabs and fill in a questionnaire. Subsequently, all individuals will see a professional. The professional will collect skin samples and swabs as well.
Eligibility Criteria
You may qualify if:
- years or older
- Have either suspected scabies, clinical scabies or confirmed scabies (see table 1)
- Providing informed consent (IC)
You may not qualify if:
- Individuals not speaking or understanding the Dutch or English language.
- Individuals who have been diagnosed with scabies in the last six weeks and had started treatment.
- Individuals who have used ivermectin for other diagnoses than scabies in the last six weeks.
- Individuals younger than 18 years.
- Individuals with immunosuppressive conditions (see appendix A).
- Any other condition, finding or situation which, in the opinion of the investigator, may significantly increase the risk to the individual because of participation in the study, affect the ability of the individual to participate in the study or impair interpretation of the study data.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Radboudumc
Nijmegen, Gelderland, 6525GA, Netherlands
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- early phase 1
- Allocation
- NA
- Masking
- NONE
- Purpose
- DIAGNOSTIC
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 26, 2024
First Posted
August 9, 2024
Study Start
August 21, 2024
Primary Completion
June 1, 2025
Study Completion
June 1, 2025
Last Updated
August 9, 2024
Record last verified: 2024-07
Data Sharing
- IPD Sharing
- Will not share